Historical News

321 Results

VIEW OPTIONS

Lotus Reports August 2026 Revenue of NT$2,107 Million

Investors

Sep 10, 2026

Lotus Reports August 2026 Revenue of NT$2,107 Million

Taipei, Taiwan, 10 September 2026 — Lotus Pharmaceutical Co., Ltd. (Taiwan Stock Exchange: 1795), a global pharmaceutical leader based in Taiwan, today announced its unaudited consolidated revenue for August 2026 of NT$2,107 million, repre...

Lotus Pharmaceutical Wins Gold at the 2026 Taiwan Sustainable Action Awards (TSAA) for Advancing Healthcare Access

ESG

Aug 27, 2026

Lotus Pharmaceutical Wins Gold at the 2026 Taiwan Sustainable Action Awards (TSAA) for Advancing Healthcare Access

Taipei, Taiwan, 27 August 2026 — Lotus Pharmaceutical Co., Ltd. (Taiwan Stock Exchange: 1795), a leading global pharmaceutical company, today announced that it has received the Gold Award in the Social Inclusion category at the 2026 Taiwan Sust...

Lotus Pharmaceutical Announces Favorable U.S. Appeals Court Ruling on Norwich’s Application for Generic Rifaximin

Business

Aug 26, 2026

Lotus Pharmaceutical Announces Favorable U.S. Appeals Court Ruling on Norwich’s Application for Generic Rifaximin

Taipei, Taiwan and Morristown, N.J., 26 August 2026 — Lotus Pharmaceutical Co., Ltd. (Taiwan Stock Exchange: 1795), a leading global pharmaceutical company, today announced that Norwich Pharmaceuticals, Inc. (“Norwich”), a wholly ow...

Lotus Pharmaceutical Announces Licensing and Commercialization Agreement with Alvotech for Biosimilar Candidates to Durvalumab and Emicizumab in the U.S. and Selected Asian Markets

Business

Aug 21, 2026

Lotus Pharmaceutical Announces Licensing and Commercialization Agreement with Alvotech for Biosimilar Candidates to Durvalumab and Emicizumab in the U.S. and Selected Asian Markets

Taipei, Taiwan, 21 August 2026 — Lotus Pharmaceutical Co., Ltd. (“Lotus”, TWSE Stock Code: 1795), a leading multinational pharmaceutical company, today announced a strategic licensing and commercialization agreement with Alvotech (N...

Lotus Pharmaceutical Receives PMDA Approval for Generic Pomalidomide Capsules in Japan

Business

Aug 19, 2026

Lotus Pharmaceutical Receives PMDA Approval for Generic Pomalidomide Capsules in Japan

Taipei, Taiwan, 19 August 2026 — Lotus Pharmaceutical Co., Ltd. (Taiwan Stock Exchange: 1795), a leading global pharmaceutical company, today announced that its generic version of POMALYST® (pomalidomide) capsules, in 1 mg, 2 mg, 3 mg and 4...

Lotus Honoured as One of Asia’s Best Workplaces for the Fifth Consecutive Year

ESG

Aug 18, 2026

Lotus Honoured as One of Asia’s Best Workplaces for the Fifth Consecutive Year

Taipei, Taiwan, 18 August 2026 — Lotus Pharmaceutical Co., Ltd. (“Lotus”, TWSE Stock Code: 1795), a leading multinational pharmaceutical company, proudly announces that it has been named a recipient of the HR Asia Best Companies to ...

Lotus Pharmaceutical Reports Record Revenue in First Half 2026 and Improved Second-Quarter Profitability

Investors

Aug 13, 2026

Lotus Pharmaceutical Reports Record Revenue in First Half 2026 and Improved Second-Quarter Profitability

Taipei, Taiwan, 13 Aug 2026 — Lotus Pharmaceutical (1795:TT; “Lotus” or “the Company”), a multinational pharmaceutical company, announced its financial results for the first half and second quarter ended 30 June 2026, se...

Lotus Reports July 2026 Revenue of NT$2,492 Million

Investors

Aug 10, 2026

Lotus Reports July 2026 Revenue of NT$2,492 Million

Taipei, Taiwan, 10 August 2026 — Lotus Pharmaceutical Co., Ltd. (Taiwan Stock Exchange: 1795), a global pharmaceutical leader based in Taiwan, today announced its unaudited consolidated revenue for July 2026 of NT$2,492 million, representi...

Alvogen Korea Recognised at the Social Contribution Company Awards

ESG

Jul 29, 2026

Alvogen Korea Recognised at the Social Contribution Company Awards

Taipei, Taiwan and Seoul, South Korea, 29 July 2026 — Lotus Pharmaceutical Co., Ltd. (Taiwan Stock Exchange: 1795, “Lotus” or the “Company”), a global pharmaceutical company headquartered in Taiwan, today announced that ...